secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001157523-23-000722
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra Q1 net loss $15.6M; PDUFA dates set; clinical readouts in Q2 2023
-------------------------------------------------------------------------

- Net loss $15.6M ($0.27 loss per share) vs $16.8M ($0.29) in Q1 2022.
- Cash and equivalents $165.0M; projected runway into H2 2024.
- PDUFA dates: ADX-2191 (June 21, 2023) for vitreoretinal lymphoma; reproxalap (Nov 23, 2023) for dry eye.
- Top-line Q2 2023: Phase 2 ADX-2191 (retinitis pigmentosa), Phase 2 ADX-629 (chronic cough), Phase 3 INVIGORATE-2 (allergic conjunctivitis).
- Aldeyra will discontinue quarterly earnings conference calls, citing shift to clinical/regulatory updates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000115752323000722/0001157523-23-000722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000115752323000722/a53393376.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer